

Curriculum Vitae and List of Publications

Dr. Hussein Osamah
Faculty of Medicine
Bar-Ilan university

List of publications

1. Hypothesis-driven research:

1. **Hussein O**, Brook GJ, Aviram M. Intraperitoneal injection of platelet secretory products into mice increases macrophage uptake of oxidized low density lipoprotein. *Isr J Med Sci.* 1993;29:453-9.
2. **Hussein O**, Rosenblat M, Schlesinger S, Keidar S, Aviram M. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. *Br J Clin Pharmacol.* 1997 Jul;44(1):77-83
3. **Hussein O**, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. *Atherosclerosis.* 1997;128:11-8.
4. **Hussein O**, Rosenblat M, Refael G, Aviram M. Dietary selenium increases cellular glutathione peroxidase activity and reduces the enhanced susceptibility to lipid peroxidation of plasma and low-density lipoprotein in kidney transplant recipients. *Transplantation* 1997;63:679-85.
5. Groshar D, Gorenberg M, **Hussein O**. Quantitative SPET 99Tcm-DMSA uptake by the kidneys: age-related decline in healthy males. *Nucl Med Commun.* 1998; 19:893-7.
6. Aviram M, **Hussein O**, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. *J Cardiovasc Pharmacol.* 1998;31:39-45.
7. **Hussein O**, Schneider J, Rosenblat M, Aviram M. Valsartan therapy has additive antioxidative effect to that of fluvastatin therapy against LDL oxidation: studies in hypercholesterolemic and hypertensive patients. *J Cardiovasc Pharmacol.* 2002;40:28-34.
8. **Hussein O**, Radan A, Viskoper R. Effect of Cilazapril with or without low dose thiazide on LDL peroxidation in hypertensive patients. *Am J Hypertension* 2003;16:734-8.
9. Assy N, Schlesinger S, Miron D, **Hussein O**. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in cirrhotic patient. *World J Gastroenterol* 2005;11:6407-6408.

10. Assy N, Grozovski M, Bersudsky I, Szalb S., **Hussein O**. Effect of insulin sensitizing agents in combination with ezetimibe and valsartan in rats with non-alcoholic fatty liver disease. *World J Gastroenterol* 2006;12:4369-76.
11. Assy N, Kayal m, Mejirisky Y, Gorenberg M, **Hussein O**, Schlesinger S. The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis. *BMC Gastroenterol* 2006;29:6:39.
12. **Hussein O**, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N. Monounsaturated fat decreases hepatic lipid content in nonalcoholic fatty liver disease in rats. *World J Gastroenterol* 2007;13:361-8.
13. **Hussein O**, Gefen Y, Karochero E, Zidan J, Luder A, Assy N, Srer ES, Aviram M. The Contribution of LDL Tendency to Peroxidation to Plasma Hemoglobin A_{1c} Level in Diabetic Patients. *Clinica Chimica Acta* 2007;377:114-8.
14. Assy N, **Hussein O**, Abdallah K, Luder A, Svalb S, Paizi M, Spira G. The beneficial effect of aspirin and enoxaprin on fibrosis progression and regenerative activity in a rat model of cirrhosis. *Dig Dis Sci* 2007;52:1187-93.
15. **Hussein O**, Schlesinger S, Svalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with non alcoholic steatohepatitis (NASH). *Dig Dis Sci* 2007;52:2512-9
16. Assy N, **Hussein O**, Abassi Z. Weight loss induced by orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with non alcoholic steatohepatitis. *Gut* 2007;56:443-4.
17. Assy N, Gefen H, Schlesinger S, **Hussein O**. The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure. *Dig Dis Sci* 2007;52:3507-10.
18. **Hussein O**, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolemia as monotherapy or in addition to simvastatin. *Br J Clin Pharmacol*. 2008;65:637-45.
19. Zidan J, **Hussein O**, Abzah A, Tamam S, Farraj Z, Friedman E. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. *Med Oncol* 2008;25:274-8.
20. Zidan J, Chetver L, **Hussein O**, Zucker M. Effect of letrozole on plasma lipids, triglycerides and estradiol in postmenopausal women with metastatic breast cancer. *The oncologist* 2010;15:1159-63.
21. Lahoud Y, **Hussein O**, Shalabi A, Nativ O, Awad H, Khamaisi M, Matar I, Nativ O, Abassi Z. Effects of Phosphodiesterase-5 Inhibitor on Ischemic Kidney Injury During Nephron Sparing Surgery: Quantitative Assessment by NGAL and KIM-1. Accepted to WJUR April 2015.
22. **Hussein O**, Izikson L, Bathish Y, Dabur E, Hanna A, Zidan J. Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy. Accepted 1 July 2015 *J Psychopharm* 2015.

B.Clinical Descriptive research

1. **Hussein O**, Svalb S, Van den Akker-Berman LM, Assy N. Liver regeneration is not altered in patients with non alcoholic steatohepatitis (NASH) when compared to chronic hepatitis infection with similar grade of inflammation. *Dig Dis Science*. 2002;47:1926-31.
2. Falik-Zaccai TC, Haron Y, Eilat D, Harash B, Golinker E, **Hussein O**, Eisikovits R, Borochoowitz Z, Linn S. Coronary heart disease among Circassians in Israel is not associated with mutations in thrombophilia genes. *Human Biol* 2003;75:57-68.
3. Zidan J, **Hussein O**, Basher W, Zohar S. Serum CA125: A tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. *The Oncologist* 2004;9: 417-21.
4. Assy N, Schlesinger S, **Hussein O**. Elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD). *Gut* 2005;54:729.
5. Assy N, Bekirov I, Mejritzky Y, Solomon L, Szvalb S, **Hussein O**. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. *World J Gastroenterol* 2005;11:5834-39. Haron Y, **Hussein O**, Epshtein L, Eilat D, Harash B, Linn S. Type 2 diabetes among circassians in Israel. *IMAJ* 2006;8:622-626.
6. **Hussein O**, Zidan J, Plich M, Gefen H, Klein R, Shestatski K, Abu-Jabal K, Zimlichman R Arterial Elasticity in Obese Subjects with Coronary Slow Flow Phenomenon. *IMAJ* 2013;15:753-7
7. Tawfeg Ben-Omran, Luis Masana, Genovefa Kolovou, Gema Ariceta, F Javier N6voa, Allan M Lund, Martin P Bogsrud, Mar6a Araujo, **Osamah Hussein**, Daiana Ibarretxe, Rosa M Sanchez-Hern6ndez, Raul D Santos. Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. *Advances in Therapy* 2019 accepted.
8. Zidan J, Mzalbat R, Sharabi A, Stein M, **Hussein O**. Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue in the same patients. *Ann Breast Cancer* 2019. Accepted.
9. Regev-Avraham T, Rozenfeld I, Yisraeli Z, Hussein O, Halabi M. Lipid profile as a strong indicator of coronary plaques: Noninvasive assessment by multislice computerized tomography. *Coronary artery disease* . Online ahead of print Nov 13, 2020.
10. Neuenschwander FC, **Osamah Hussein**, Mark L. Levitt. Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO2 Requirements. *Microorganisms* 2024, 12, 1767. <https://doi.org/10.3390/microorganisms12091767>

C. Case reports

1. Miron D, Olshink A, Assy N, Zucker M, Efrat M, **Hussein O**. Plasmodium Malaria and borrelia co-infection. *J Travel Med* 2004;11:115-6.

2. Assy N, Khair G, Schlesinger S, **Hussein O**. Severe cholestatic jaundice in the elderly induced by low dose amiodarone. *Dig Dis Sci* 2004;49:450-2. (Gastroenterology and Hepatology)
3. Assy N, Schlesinger S, **Hussein O**. Acute hepatitis with extremely high ferritin levels and still's disease. *J Hepatology*. 2001,35:830-31. (Gastroenterology and Hepatology)
4. **Hussein O**, Finkelstein R, Brook JG. Rhabdomyolysis complicating acute Epstein-Barr virus infection. *Infection*. 1995 Mar-Apr;23(2):119-20.

D. Review papers:

1. **Hussein O**, Traub YM. Triglycerides and atherosclerosis: update and therapeutic recommendations. *Harefuah*. 1994;126:593-7. Review. Hebrew.
 2. **Hussein O**, Traub YM. Should serum cholesterol be checked in children? *Harefuah*. 1993;125:225-7. Review. Hebrew.
 3. **Hussein O**, Levy Y, Brook G. Pulmonary involvement in Behcet's disease. *Harefuah*. 1991;120:542-4. Review. Hebrew.
-
1. Assy N, **Hussein O**. Peginterferon and lamivudine for hepatitis B. Letter to the Editor. *New Engl J Med* 2004;351:27.
 1. **Hussein O**, Brook JG, Aviram M. Inhibition of cellular uptake of low- density lipoprotein by mouse peritoneal macrophages that were pre- exposed in vivo to platelet secretory products. *Harefuah*. 1993 Mar 1;124(5):277-81.
 2. **Hussein O**, Frydman G, Frim H, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. *Pathophysiology*. 2001;8:21-28.
 3. Edoute Y, **Hussein O**, Malberger E, Yerushalmi R, Tibon-fisher O, Assy N. Diagnostic accuracy of direct fine-needle aspiration of liver lesions: A prospective study of 107 patients in peripheral community center with limited technological capability. *Arch Gastroenterohepatol* 2001;20:19-24, (editorial20:14-8).
 4. **O. Hussein**, K. Abu Gabal, J. Zidan, I. Shams, M. Grozovski, I. Bersudsky, R Karry, M. Aviram. Paraonase activity and expression is modulated by therapeutics in experimental rat non-alcoholic fatty liver disease. *Internat J Hepatology* 2012;2012, article ID 265305.
 5. **Hussein O**, Karen Drumea, Zidan J. Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment. *Indian J Med Paediatr Oncol* 2013;34:234-7.
 6. Abu-Saleh J, **Hussein O**, Hamzi S, Zidan J. Effect of young age on clinical, pathological features and survival of patients with colorectal cancer. *Harefuah* 2016;155:219-222. Hebrew.

